Major depressive disorder (MDD) is a common, serious, debilitating condition affecting 350
million people worldwide, which remains to be unsatisfactorily treated with 53% of patients …

An intranasal formulation of esketamine, the S enantiomer of ketamine, in conjunction with
an oral antidepressant, has been approved by the FDA for treating treatment-resistant major …

Ketamine and related drugs are arguably one of the most exciting developments in
antidepressant pharmacology in more than half a century and are a potentially new …

Recently, the United States Food and Drug Administration approved esketamine, the S-
enantiomer of ketamine, as a fast-acting therapeutic drug for treatment-resistant depression …

Ketamine is an anesthetic known globally both for its potent dissociative properties and
potential for abuse. More recently, ketamine demonstrates utility in a variety of disease …

Over the past two decades, ketamine has emerged as a novel effective and rapid-acting
antidepressant. While the vast majority of studies on ketamine have focused on its ability to …

Ketamine, an N-methyl-D-aspartate receptor antagonist, is widely known as a dissociative
anesthetic and phencyclidine derivative. Due to an undesirable adverse event profile when …

Major depressive disorder (MDD) is a serious psychiatric illness that causes functional
impairment in many people. While monoaminergic antidepressants have been used to …

Ketamine, a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, has been
exclusively used as an anesthetic in medicine and has led to new insights into the …

Ketamine [2-(2-chlorophenyl)-2-(methylamino) cyclohexanone] is a dissociative anaesthetic,
first developed in 1963 by Parke-Davis. It finds widespread application in the treatment of …